Name | No. | For Patients with | Purpose |
---|---|---|---|
Mountaineer-03 | 23-25 | Patients with HER2 positive colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). |
The main objective of the study is to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also test what side effects happen when participants take this combination of drugs. |
DSSG Group: Gastrointestinal
FORTITUDE-101
Name | No. | For Patients with | Purpose |
---|---|---|---|
FORTITUDE-101 | 23-17 | Suitable for adult patients with previously untreated Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression |
The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants with Fibroblast Growth Factor Receptor 2b (FGFR2b) over expression. |
PaTcH Trial
Name | No. | For Patients with | Purpose |
---|---|---|---|
PaTcH Trial | 20-27 | Metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine |
The goal of this study is to examine if Trametinib and Hydroxychloroquine will improve results for patients with advanced pancreatic cancer compared to standard chemotherapy. |
KRYSTAL-10
Name | No. | For Patients with | Purpose |
---|---|---|---|
KRYSTAL-10 | 21-06 | Advanced Colorectal Cancer with KRAS G12C mutation with disease progression on or after standard first line therapy |
To compare the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation. |
HERIZON-GEA-01 (ZWI-ZW25-301) Zymeworks
Name | No. | For Patients with | Purpose |
---|---|---|---|
HERIZON-GEA-01 (ZWI-ZW25-301) Zymeworks | 21-35 | The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic) |
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. |
DESTINY DS8201-A-U306
Name | No. | For Patients with | Purpose |
---|---|---|---|
DESTINY DS8201-A-U306 | 21-07 | HER-2 positive metastatic and/or unresectable gastric or gasto-esophageal junction (GEJ) cancer |
This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd), a HER-2 targeting antinbody drug, compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) cancer who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy. |
Astellas 8951-CL-5201
Name | No. | For Patients with | Purpose |
---|---|---|---|
Astellas 8951-CL-5201 | CTRIAL-IE 18-44 | Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma |
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM, and health-related quality of life (HRQoL). |